Endothelin therapeutics in cancer: Where are we?

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 310, Issue 6, 2016, Pages R469-R475

  Rosanò, Laura ^a   Bagnato, Anna ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cancer; Endothelin 1; Endothelin 1 receptor; Target therapy; arrestin

Indexed keywords

BETA ARRESTIN 1; BIOLOGICAL MARKER; ENDOTHELIN 1; MACITENTAN; MOLECULAR THERAPY AGENT; ANTINEOPLASTIC AGENT; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; TUMOR MARKER;

CANCER CELL; CANCER RESISTANCE; CANCER THERAPY; CELL INTERACTION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFICACY; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; INTRACELLULAR SIGNALING; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE; PRECLINICAL STUDY; PRIORITY JOURNAL; REVIEW; TUMOR BIOPSY; TUMOR MICROENVIRONMENT; ANIMAL; DRUG EFFECTS; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; ENDOTHELIN-1; HUMANS; NEOPLASMS; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B;

EID: 84984843587     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00532.2015     Document Type: Review

References (35)

1. The. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615, 2011.
2. Bhalla S, Pais G, Tapia M, Gulati A. Endothelin ETA receptor antagonist reverses naloxone-precipitated opioid withdrawal in mice. Can J Physiol Pharmacol 93: 935-944, 2015.
3. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci USA 103: 1492-1497, 2006.
4. Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, Katsaros D, O’Brien-Jenkins A, Gimotty PA, Coukos G. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nature Med 14: 28-36, 2008.
5. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401-404, 2012.
6. Chen CC, Chen LL, Hsu YT, Liu KJ, Fan CS, Huang TS. The endothelin-integrin axis is involved in macrophage-induced breast cancer cell chemotactic interactions with endothelial cells. J Biol Chem 289: 10029-10044, 2014.
7. Cianfrocca R, Tocci P, Semprucci E, Spinella F, Di Castro V, Bagnato A, Rosanò L. β-Arrestin 1 is required for endothelin-1-induced NF-κB activation in ovarian cancer cells. Life Sci 118: 179-184, 2014.
8. Coffman L, Mooney C, Lim J, Bai S, Silva I, Gong Y, Yang K, Buckanovich RJ. Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells. Cancer Biol Ther 14: 184-92, 2013.
9. Cruz-Muñoz W, Jaramillo ML, Man S, Xu P, Banville M, Collins C, Nantel A, Francia G, Morgan SS, Cranmer LD, O’Connor-McCourt MD, Kerbel RS. Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma. Cancer Res 72: 4909-4919, 2012.
10. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: pl1, 2013.
11. Guruli G, Pflug BR, Pecher S, Makarenkova V, Shurin MR, Nelson JB. Function and survival of dendritic cells depend on endothelin-1 and endothelin receptor autocrine loops. Blood 104: 2107-2115, 2004.
12. Huang WH, Chang MC, Tsai KS, Hung MC, Chen HL, Hung SC. Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. Oncogene 32: 4343-4354, 2013.
13. Kim SJ, Kim JS, Kim SW, Yun SJ, He J, Brantley E, Fan D, Strickner P, Lehembre F, Regenass U, Fidler IJ. Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist. Transl Oncol 5: 39-47, 2012.
14. Kim SJ, Lee HJ, Kim MS, Choi HJ, He J, Wu Q, Aldape K, Weinberg JS, Yung WK, Conrad CA, Langley RR, Lehembre F, Regenass U, Fidler IJ. Macitentan, a dual endothelin receptor antagonist, in combination with temozolomide leads to glioblastoma regression and long-term survival in mice. Clin Cancer Res 21: 4630-4641, 2015.
15. Kim SW, Choi HJ, Lee HJ, He J, Wu Q, Langley RR, Fidler IJ, Kim SJ. Role of the endothelin axis in astrocyte-and endothelial cell-mediated chemoprotection of cancer cells. Neuro Oncol 12: 1585-1598, 2014.
16. Knowles JP, Shi-Wen X, Haque SU, Bhalla A, Dashwood MR, Yang S, Taylor I, Winslet MC, Abraham DJ, Loizidou M. Endothelin-1 stimulates colon cancer adjacent fibroblasts. Int J Cancer 130: 1264-1272, 2012.
17. Maffei R, Bulgarelli J, Fiorcari S, Martinelli S, Castelli I, Valenti V, Rossi D, Bonacorsi G, Zucchini P, Potenza L, Vallisa D, Gattei V, Del Poeta G, Forconi F, Gaidano G, Narni F, Luppi M, Marasca R. Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptor. PLos One 9: e98818, 2014.
18. Maguire JJ, Kuc RE, Pell VR, Green A, Brown M, Kumar S, Wehrman T, Quinn E, Davenport AP. Comparison of human ETA and ETB receptor signalling via G-protein and β-arrestin pathways. Life Sci 91: 544-549, 2012.
19. Nakashima S, Sugita Y, Miyoshi H, Arakawa F, Muta H, Ishibashi Y, Niino D, Ohshima K, Terasaki M, Nakamura Y, Morioka M. Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas. J Neurooncol 2015 Dec 8. [Epub ahead of print]
20. Pillai S, Trevino J, Rawal B, Singh S, Kovacs M, Li X, Schell M, Haura E, Bepler G, Chellappan S. β-arrestin-1 mediates nicotineinduced metastasis through E2F1 target genes that modulate epithelialmesenchymal transition. Cancer Res 75: 1009-1020, 2015.
21. Rajeshkumar NV, Matwyshyn G, Gulati A. IRL-1620, a tumor selective vasodilator, augments the uptake and efficacy of chemotherapeutic agents in prostate tumor rats. Prostate 67: 701-713, 2007.
22. Rosanò L, Spinella F, Di Castro V, Nicotra MR, Dedhar S, de Herreros AG, Natali PG, Bagnato A. Endothelin-1 promotes epithelialto-mesenchymal transition in human ovarian cancer cells. Cancer Res 65: 11649-11657, 2005.
23. Rosanò L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A, Salvati E, Nicotra MR, Natali PG, Bagnato A. Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci USA 106: 2806-2811, 2009.
24. Rosanò L, Spinella F, Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 13: 637-651, 2013.
25. Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Caprara V, Semprucci E, Ferrandina G, Natali PG, Bagnato Aβ-arrestin-1. is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling. Oncogene 32: 5066-5077, 2013.
26. Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Caprara V, Semprucci E, Ferrandina G, Natali PG, Bagnato A. Endothelin A receptor/β-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy. Cancer Res 74: 7453-7464, 2014.
27. Said N, Smith S, Sanchez-Carbayo M, Theodorescu D. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest 121: 132-147, 2011.
28. Semprucci E, Tocci P, Cianfrocca R, Sestito R, Caprara V, Veglione M, Castro VD, Spadaro F, Ferrandina G, Bagnato A, Rosanò L. Endothelin A receptor drives invadopodia function and cell motility through the β-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma. Oncogene 2015. doi:10.1038/onc.2015.403.
29. Sestito R, Cianfrocca R, Rosanò L, Tocci P, Semprucci E, Di Castro V, Caprara V, Ferrandina G, Sacconi A, Blandino G, Bagnato A. miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. Oncotarget 2015 doi:10.18632/oncotarget.6546.
30. Spinella F, Caprara V, Di Castro V, Rosanò L, Cianfrocca R, Natali PG, Bagnato A. Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. J Mol Med 91: 395-405, 2013.
31. Spinella F, Caprara V, Cianfrocca R, Rosanò L, Di Castro V, Garrafa E, Natali PG, Bagnato A. The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor. Carcinogenesis 35: 840-848, 2014.
32. Tanaka T, Sho M, Takayama T, Wakatsuki K, Matsumoto S, Migita K, Ito M, Hamada K, Nakajima Y. Endothelin B receptor expression correlates with tumour angiogenesis and prognosis in oesophageal squamous cell carcinoma. Br J Cancer 110: 1027-1033, 2014.
33. Teoh JP, Park KM, Wang Y, Hu Q, Kim S, Wu G, Huang S, Maihle N, Kim IM. Endothelin-1/endothelin A receptor-mediated biased signaling is a new player in modulating human ovarian cancer cell tumorigenesis. Cell Signal 26: 2885-2895, 2014.
34. Wu MH, Huang CY, Lin JA, Wang SW, Peng CY, Cheng HC, Tang CH. Endothelin-1 promotes vascular endothelial growth factor-dependent angiogenesis in human chondrosarcoma cells. Oncogene 33: 1725-1735, 2014.
35. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415, 1988.